

Supporting Information
of
Highly diastereoselective synthesis of
3-hydroxy-2,2,3-trisubstituted indolines *via* intramolecular
trapping of ammonium ylides with ketones

Changcheng Jing, Dong Xing and Wenhao Hu*

Shanghai Engineering Research Centre of Molecular Therapeutics
and New Drug Development
East China Normal University, Shanghai, 200062, China

whu@chem.ecnu.edu.cn

Table of Contents

	Page
1. General Information.....	S1
2. Typical procedure for the Reaction.....	S2
3. Table S1 and S2 for detailed condition optimizations.....	S3
4. X-ray diffraction parameters and data for <i>cis</i> - 3a and <i>cis</i> - 8h	S4-S6
5. Notes and References.....	S7
6. Analytical Data for the Products.....	S8-S17
7. NMR spectra for the Products.....	S18-S46

1. General Information:

All solvents were purified and dried using standard procedures. Diazo compounds **1**,¹ 2'-Aminochalcones **2**,² and 2-(*N*-alkylamino)phenyl ketones **7**³ were prepared according to literature procedures. All NMR spectra were recorded on a Bruker spectrometer at 400 MHz (¹H NMR) and 100 MHz (¹³C NMR). Chemical shifts (δ value) were reported in ppm down field from internal tetramethylsilane (TMS). HRMS (ESI) Mass Spectra were recorded on IonSpec FT-ICR mass spectrometer.

2. Experimental Procedures

2.1 General procedure for Rh₂(OAc)₄-catalyzed reaction of diazo compounds and 2'-aminochalcones:

Diazo compound **1** (0.48 mmol) in 1.5 mL of CH₂Cl₂ was added to the mixture of **2** (0.30 mmol), Rh₂(OAc)₄ (1.0 mmol%) and 4 Å MS (300 mg) in 1.5 mL of CH₂Cl₂ *via* syringe pump over 1 h at 40 °C. The reaction mixture was purified by flash chromatography on silica gel to give pure *cis*-**3**.

2.2 General procedure for Rh₂(OAc)₄-catalyzed reaction of diazo compounds and 2-(*N*-alkylamino)phenyl ketones:

Diazo compound **1** (0.36 mmol) in 1.5 mL of toluene was added to the mixture of **7** (0.30 mmol), Rh₂(OAc)₄ (1.0 mmol%), 4 Å MS (300 mg) in 1.5 mL of toluene *via* syringe pump over 1 h at 25 °C. The reaction mixture was purified by flash chromatography on silica gel to give pure *cis*-**8**.

2.3 Procedure for the reaction between aryldiazoacetate **1a** and 2'-aminoacetophenone **4a**:


1a (0.24 mmol) in CH₂Cl₂ (1.0 mL) was added to a mixture of **4a** (0.20 mmol) and Rh₂(OAc)₄ (1 mol%) in CH₂Cl₂ (1.0 mL) over a period of 1 h *via* syringe pump at 25 °C. The reaction mixture was purified by flash chromatography to give pure **5a** (48.2mg, 85% yield).

2.4 Procedure for preparation of compound **9** from *cis*-**8a**:

A mixture of compound *cis*-**8a** (29.7 mg, 0.10 mmol), *p*-toluenesulfonic acid monohydrate (3.8 mg, 0.02 mmol) and cyclohexane (1.0 mL) was refluxed for 2 h under azeotropic distillation. TLC indicated the reaction was complete. The reaction mixture was cooled to room temperature. The solvent was removed under vacuum to give the crude product. The resulted crude product was purified by column chromatography on silica gel to give the product **9** (25.0 mg, 90% yield).

3. Table S1 and S2 for detailed condition optimizations.


Table S1 Condition optimization for Rh₂(OAc)₄-catalyzed reaction of **1a** and **2a**.^a



Entry	Solvent	<i>T</i> (°C)	Eq.(1a : 2a)	Yield (%) ^b	Dr ^c
1 ^d	CH ₂ Cl ₂	40	1.4:1.0	72	>95:5
2	CH ₂ Cl ₂	40	1.4:1.0	87	>95:5
3	DCE	40	1.4:1.0	81	>95:5
4	toluene	40	1.4:1.0	75	>95:5
5	CH ₂ Cl ₂	25	1.4:1.0	79	>95:5
6	CH ₂ Cl ₂	40	1.6:1.0	94	>95:5

^a Unless otherwise noted, the reaction was carried out on a 0.10 mmol scale. Methyl phenyldiazoacetate **1a** in 0.5 mL of solvent was added to the mixture of **2a**, Rh₂(OAc)₄ (1.0 mmol%) and 4 Å MS (100 mg) within 1 h *via* syringe pump. ^b Isolated yield. ^c Determined by ¹H NMR spectroscopy of the crude reaction mixture. ^d Without the addition of 4 Å MS.

Table S2 Condition optimization for Rh₂(OAc)₄-catalyzed reaction of **1a** and **7a**.^a




Entry	Solvent	<i>T</i> (°C)	Yield (%) ^b	Dr ^c
1	CH ₂ Cl ₂	25	89	>95:5
2	toluene	25	97	>95:5
3	DCE	25	90	>95:5
4	toluene	40	96	>95:5
5	toluene	0	93	>95:5

^a Unless otherwise noted, the reaction was carried out on a 0.10 mmol scale, **1a**:**7a** = 1.2:1.0. Aryldiazoacetate **1a** (0.12 mmol) in 0.5 mL of solvent was added to the mixture of **7a** (0.10 mmol), Rh₂(OAc)₄ (1.0 mmol%), 4 Å MS (100 mg) in 0.5 mL of solvent *via* syringe pump over 1 h. ^b Isolated yield of **8a**. ^c Determined by ¹H NMR of the crude reaction mixture.

4. X-ray diffraction parameters and data


4.1. X-ray diffraction parameters and data for *cis*-3a (CCDC 957672)



Identification code	z	
Empirical formula	C ₂₄ H ₂₁ N O ₃	
Formula weight	371.42	
Temperature	173(2) K	
Wavelength	0.71073 Å	
Crystal system, space group	Orthorhombic, P ₆ ca	
Unit cell dimensions	a = 10.7586(6) Å	alpha = 90 deg.
	b = 16.5601(10) Å	beta = 90 deg.
	c = 21.4710(13) Å	gamma = 90 deg.
Volume	3825.3(4) Å ³	
Z, Calculated density	8, 1.290 Mg/m ³	
Absorption coefficient	0.085 mm ⁻¹	
F(000)	1568	
Crystal size	0.55 x 0.45 x 0.24 mm	
Theta range for data collection	1.90 to 25.01 deg.	
Limiting indices	-12 ≤ h ≤ 12, -19 ≤ k ≤ 19, -25 ≤ l ≤ 25	
Reflections collected / unique	41206 / 3370 [R(int) = 0.0502]	
Completeness to theta = 25.01	100.0 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	0.9799 and 0.9548	
Refinement method	Full-matrix least-squares on F ²	
Data / restraints / parameters	3370 / 0 / 253	

Goodness-of-fit on F^2	1.026
Final R indices [$I > 2\sigma(I)$]	$R1 = 0.0460$, $wR2 = 0.1189$
R indices (all data)	$R1 = 0.0550$, $wR2 = 0.1283$
Largest diff. peak and hole	0.563 and -0.621 $e.\text{Å}^{-3}$

4.2. X-ray diffraction parameters and data for *cis*-8h (CCDC 957673)



Identification code	z
Empirical formula	C ₂₅ H ₂₅ N O ₃
Formula weight	387.46
Temperature	296(2) K
Wavelength	0.71073 Å
Crystal system, space group	Monoclinic, P2(1)/c
Unit cell dimensions	$a = 10.0938(5)$ Å $\alpha = 90$ deg. $b = 19.9876(10)$ Å $\beta = 115.150(2)$ deg. $c = 11.2239(6)$ Å $\gamma = 90$ deg.
Volume	$2049.76(18)$ Å ³
Z, Calculated density	4, 1.256 Mg/m ³
Absorption coefficient	0.082 mm ⁻¹
F(000)	824
Crystal size	0.24 x 0.19 x 0.12 mm
Theta range for data collection	2.23 to 25.01 deg.
Limiting indices	$-12 \leq h \leq 12$, $-23 \leq k \leq 23$, $-13 \leq l \leq 13$
Reflections collected / unique	23363 / 3577 [$R(\text{int}) = 0.0477$]
Completeness to theta = 25.01	99.0 %

Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.9902 and 0.9806
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	3577 / 0 / 262
Goodness-of-fit on F ²	1.022
Final R indices [I > 2σ(I)]	R1 = 0.0639, wR2 = 0.1741
R indices (all data)	R1 = 0.0930, wR2 = 0.2001
Largest diff. peak and hole	1.183 and -0.272 e.Å ⁻³


5. Notes and References

1. Doyle, M. P., Mckerverey, M. A. and Ye, T. *Modern Catalytic Methods for Organic Synthesis with Diazo Compounds*; Wiley: New York, (1998).
2. Y. Xia, Z-Y Yang, P Xia, K. F. Bastow, Y. Tachibana, S.-C. Kuo, E. Hamel, T. Hackl, and K.-H. Lee, *J. Med. Chem.*, 1998, **41**, 1155.
3. M. Martjuga, S. Belyakov, E. Liepinsh, E. Suna, *J. Org. Chem.*, 2011, **76**, 2635; A. F. Bella, A. M. Z. Slawin, and J. C. Walton, *J. Org. Chem.*, 2004, **69**, 5926.

6. Analytical Data for the Products

6.1 Analytical Data for 3


(2*S**,3*R**)-methyl 3-hydroxy-2-phenyl-3-((*E*)-styryl)indoline-2-carboxylate (**3a**)



^1H NMR (400 MHz, CDCl_3) δ 7.60-7.58 (m, 2H), 7.32-7.29 (m, 3H), 7.21-7.12 (m, 5H), 7.03-7.01 (m, 2H), 6.86-6.82 (m, 2H), 6.43 (d, $J = 15.9$ Hz, 1H), 5.73 (d, $J = 15.9$ Hz, 1H), 5.11 (s, 1H), 4.76 (s, 1H), 3.70 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.61, 147.49, 136.98, 136.69, 131.92, 129.93, 129.59, 128.97, 128.38, 128.28, 128.25, 127.24, 126.55, 126.21, 124.34, 120.61, 110.29, 85.88, 79.56, 53.01; HRMS (ESI): Exact mass calcd for $\text{C}_{24}\text{H}_{21}\text{NNaO}_3$ [$\text{M}+\text{Na}$] $^+$: 394.1414, Found 394.1408.


(2*S**,3*R**)-methyl

2-(4-bromophenyl)-3-hydroxy-3-((*E*)-styryl)indoline-2-carboxylate (**3b**)



^1H NMR (400 MHz, CDCl_3) δ 7.51-7.48 (m, 2H), 7.45-7.42 (m, 2H), 7.20-7.15 (m, 5H), 7.07-7.05 (m, 2H), 6.87-6.82 (m, 2H), 6.45 (d, $J = 15.9$ Hz, 1H), 5.71 (d, $J = 15.9$ Hz, 1H), 5.06 (s, 1H), 4.77 (s, 1H), 3.69 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.27, 147.13, 136.71, 135.81, 131.91, 131.49, 129.72, 129.37, 129.29, 128.40, 128.15, 127.48, 126.59, 124.27, 122.42, 120.93, 110.58, 85.89, 79.11, 53.24; HRMS (ESI): Exact mass calcd for $\text{C}_{24}\text{H}_{20}\text{BrNNaO}_3$ [$\text{M}+\text{Na}$] $^+$: 394.1414, Found 394.1406.

(2*S**,3*R**)-methyl 3-hydroxy-3-((*E*)-styryl)-2-(*p*-tolyl)indoline-2-carboxylate (**3c**)




^1H NMR (400 MHz, CDCl_3) δ 7.46 (d, $J = 8.2$ Hz, 2H), 7.20-7.11 (m, 7H), 7.07-7.05

(m, 2H), 6.86-6.81 (m, 2H), 6.47 (d, $J = 15.9$ Hz, 1H), 5.78 (d, $J = 15.9$ Hz, 1H), 5.12 (s, 1H), 4.76 (s, 1H), 3.69 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.77, 147.53, 138.03, 137.03, 133.59, 131.97, 129.90, 129.59, 129.15, 128.85, 128.28, 127.24, 126.62, 126.12, 124.33, 120.55, 110.27, 85.74, 79.39, 53.05, 21.15; HRMS (ESI): Exact mass calcd for $\text{C}_{25}\text{H}_{23}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$: 408.1570, Found 408.1569.

(2*S,3*R**)-methyl**


3-hydroxy-2-(3-methoxyphenyl)-3-((*E*)-styryl)indoline-2-carboxylate (3d)



^1H NMR (400 MHz, CDCl_3) δ 7.26-7.11 (m, 8H), 7.07-7.05 (m, 2H), 6.88-6.81 (m, 3H), 6.43 (d, $J = 15.9$ Hz, 1H), 5.77 (dd, $J = 15.9, 0.5$ Hz, 1H), 5.22 (d, $J = 0.6$ Hz, 1H), 4.76 (s, 1H), 3.72 (s, 3H), 3.69 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.67, 159.61, 147.37, 138.18, 136.96, 131.89, 129.84, 129.61, 129.47, 128.89, 128.30, 127.29, 126.59, 124.33, 120.65, 118.55, 113.86, 111.96, 110.32, 85.81, 79.38, 55.26, 53.13; HRMS (ESI): Exact mass calcd for $\text{C}_{25}\text{H}_{23}\text{NNaO}_4$ $[\text{M}+\text{Na}]^+$: 424.1519, Found 424.1515.

(2*S,3*R**)-methyl**

3-hydroxy-2-(2-methoxyphenyl)-3-((*E*)-styryl)indoline-2-carboxylate (3e)




^1H NMR (400 MHz, CDCl_3) δ 7.72-7.70 (m, 1H), 7.26-7.21 (m, 2H), 7.18-7.09 (m, 4H), 6.99-6.97 (m, 3H), 6.89-6.87 (m, 2H), 6.74 (d, $J = 7.8$ Hz, 1H), 6.30 (d, $J = 15.9$ Hz, 1H), 5.87 (s, 1H), 5.76 (d, $J = 15.9$ Hz, 1H), 4.32 (s, 1H), 3.78 (s, 3H), 3.66 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.80, 157.34, 146.73, 137.12, 132.33, 131.14, 129.40, 129.10, 128.22, 127.90, 127.80, 127.13, 126.87, 126.53, 124.33, 120.69,

120.54, 111.69, 109.80, 86.18, 56.08, 52.56; HRMS (ESI): Exact mass calcd for $C_{25}H_{23}NNaO_4 [M+Na]^+$: 424.1519, Found 424.1518.

(2*S,3*R**)-methyl**


3-((*E*)-4-chlorostyryl)-3-hydroxy-2-phenylindoline-2-carboxylate (3f)



1H NMR (400 MHz, $CDCl_3$) δ 7.59-7.57 (m, 2H), 7.34-7.27 (m, 3H), 7.21-7.17 (m, 2H), 7.10 (d, $J = 8.4$ Hz, 2H), 6.92 (d, $J = 8.4$ Hz, 2H), 6.88-6.82 (m, 2H), 6.35 (d, $J = 15.9$ Hz, 1H), 5.70 (d, $J = 15.9$ Hz, 1H), 5.26 (s, 1H), 4.76 (s, 1H), 3.69 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 174.76, 147.35, 136.49, 135.45, 132.85, 131.80, 130.68, 129.63, 128.41, 128.36, 127.72, 127.63, 126.09, 124.23, 120.71, 110.39, 85.79, 79.39, 53.10; HRMS (ESI): Exact mass calcd for $C_{24}H_{20}ClNNaO_3 [M+Na]^+$: 428.1024, Found 428.1017.

(2*S,3*R**)-methyl**

3-hydroxy-2-phenyl-3-((*E*)-4-(trifluoromethyl)styryl)indoline-2-carboxylate (3g)




1H NMR (400 MHz, $CDCl_3$) δ 7.61-7.59 (m, 2H), 7.39 (d, $J = 8.2$ Hz, 2H), 7.35-7.30 (m, 3H), 7.24-7.20 (m, 2H), 7.08 (d, $J = 8.1$ Hz, 2H), 6.89-6.83 (m, 2H), 6.45 (d, $J = 15.9$ Hz, 1H), 5.83 (d, $J = 15.9$ Hz, 1H), 5.36 (d, $J = 0.7$ Hz, 1H), 4.78 (s, 1H), 3.70 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 174.80, 147.28, 140.47, 140.46, 136.38, 132.68, 131.67, 129.70, 129.00 (q, $J = 257.1$ Hz), 128.47, 128.43, 127.36, 126.63, 126.04, 125.22 (q, $J = 30.2$ Hz), 124.16, 120.79, 110.46, 85.74, 79.32, 53.14; HRMS (ESI):

Exact mass calcd for $C_{25}H_{20}F_3NNaO_3$ $[M+Na]^+$: 462.1287, Found 462.1283.

(2*S,3*R**)-methyl**


3-hydroxy-3-((*E*)-4-methylstyryl)-2-phenylindoline-2-carboxylate (3h)



1H NMR (400 MHz, $CDCl_3$) δ 7.59-7.57 (m, 2H), 7.32-7.27 (m, 3H), 7.22-7.16 (m, 2H), 6.97-6.91 (m, 4H), 6.86-6.81 (m, 2H), 6.39 (d, $J = 15.9$ Hz, 1H), 5.68 (d, $J = 15.9$ Hz, 1H), 5.09 (s, 1H), 4.77 (s, 1H), 3.68 (s, 3H), 2.24 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 174.65, 147.55, 137.06, 136.75, 134.16, 131.99, 129.60, 129.00, 128.90, 128.89, 128.38, 128.27, 126.49, 126.26, 124.40, 120.58, 110.29, 85.94, 79.60, 53.04, 21.15; HRMS (ESI): Exact mass calcd for $C_{25}H_{23}NNaO_3$ $[M+Na]^+$: 408.1570, Found 408.1567.

(2*S,3*R**)-methyl**


3-hydroxy-3-((*E*)-4-methoxystyryl)-2-phenylindoline-2-carboxylate (3i)



1H NMR (400 MHz, $CDCl_3$) δ 7.59-7.57 (m, 2H), 7.34-7.28 (m, 3H), 7.21-7.17 (m, 2H), 6.96 (d, $J = 8.7$ Hz, 2H), 6.87-6.82 (m, 2H), 6.69 (d, $J = 8.7$ Hz, 2H), 6.34 (d, $J = 15.9$ Hz, 1H), 5.58 (d, $J = 15.9$ Hz, 1H), 5.08 (s, 1H), 4.76 (s, 1H), 3.72 (s, 3H), 3.70 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 174.64, 158.99, 147.53, 136.77, 132.01, 129.74, 129.56, 128.52, 128.35, 128.24, 127.79, 127.71, 126.24, 124.40, 120.56, 113.70, 110.26, 85.95, 79.59, 55.21, 53.02; HRMS (ESI): Exact mass calcd for $C_{25}H_{23}NNaO_4$ $[M+Na]^+$: 424.1519, Found 424.1516.


(2*S,3*R**)-methyl**

3-((*E*)-3-chlorostyryl)-3-hydroxy-2-phenylindoline-2-carboxylate (3j**)**




^1H NMR (400 MHz, CDCl_3) δ 7.60-7.58 (m, 2H), 7.34-7.28 (m, 3H), 7.20-7.17 (m, 2H), 7.06-7.05 (m, 2H), 6.98 (s, 1H), 6.88-6.82 (m, 3H), 6.37 (d, $J = 15.9$ Hz, 1H), 5.74 (d, $J = 15.9$ Hz, 1H), 5.30 (s, 1H), 4.78 (s, 1H), 3.68 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.79, 147.31, 138.90, 136.43, 134.17, 131.78, 131.55, 129.66, 129.48, 128.46, 128.41, 127.47, 127.17, 126.49, 126.09, 124.70, 124.18, 120.74, 110.43, 85.75, 79.37, 53.12; HRMS (ESI): Exact mass calcd for $\text{C}_{24}\text{H}_{20}\text{ClNNaO}_3$ $[\text{M}+\text{Na}]^+$: 428.1024, Found 428.1024.

(2*S,3*R**)-ethyl 3-hydroxy-2-methyl-3-((*E*)-styryl)indoline-2-carboxylate (**3k**)**



^1H NMR (400 MHz, CDCl_3) δ 7.46 (d, $J = 7.3$ Hz, 2H), 7.35 (t, $J = 7.5$ Hz, 2H), 7.28 (d, $J = 7.3$ Hz, 1H), 7.23-7.18 (m, 2H), 6.88 (d, $J = 16.1$ Hz, 1H), 6.84-6.78 (m, 2H), 6.48 (d, $J = 16.0$ Hz, 1H), 4.41 (s, 1H), 4.34-4.21 (m, 2H), 2.65 (s, 1H), 1.45 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.14, 148.74, 136.78, 131.66, 130.81, 130.42, 128.62, 127.78, 127.57, 126.71, 125.04, 120.02, 111.57, 84.64, 75.20, 61.51, 23.25, 14.23; HRMS (ESI): Exact mass calcd for $\text{C}_{20}\text{H}_{21}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$: 346.1419, Found 346.1418.


(2*S,3*R**)-methyl 3-hydroxy-2,3-diphenylindoline-2-carboxylate (**3l**)**



^1H NMR (400 MHz, CDCl_3) δ 7.27-7.23 (m, 1H), 7.21-7.19 (m, 2H), 7.14-7.12 (m, 1H), 7.10-7.03 (m, 3H), 6.99-6.92 (m, 3H), 6.90-6.90 (m, 1H), 6.88-6.85 (m, 3H), 5.57 (s, 1H), 4.70 (s, 1H), 3.72 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 175.16, 148.23, 140.13, 136.45, 133.93, 129.63, 127.73, 127.41, 126.89, 126.82, 126.03, 124.73, 120.90, 110.20, 88.18, 80.45, 53.02; HRMS (ESI): Exact mass calcd for $\text{C}_{22}\text{H}_{19}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$: 368.1257, Found 368.1261.


6.2 Analytical Data for 8 and 9

(2*S**,3*R**)-methyl 3-hydroxy-1,3-dimethyl-2-phenylindoline-2-carboxylate (8a)



^1H NMR (400 MHz, CDCl_3) δ 7.37-7.32 (m, 5H), 7.25-7.20 (m, 2H), 6.82 (t, $J = 7.4$ Hz, 1H), 6.56 (d, $J = 7.7$ Hz, 1H), 3.83 (s, 1H), 3.74 (s, 3H), 2.77 (s, 3H), 1.03 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.88, 149.47, 135.83, 134.29, 129.43, 128.10, 127.99, 127.22, 121.90, 119.13, 107.25, 86.05, 83.44, 51.78, 32.45, 25.41; HRMS (ESI): Exact mass calcd for $\text{C}_{18}\text{H}_{19}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$: 320.1257, Found 320.1286.


(2*S**,3*R**)-methyl 1-benzyl-3-hydroxy-3-methyl-2-phenylindoline-2-carboxylate (8b)



^1H NMR (400 MHz, CDCl_3) δ 7.42 (d, $J = 7.7$ Hz, 2H), 7.37-7.24 (m, 9H), 7.05-7.01 (m, 1H), 6.82 (t, $J = 7.4$ Hz, 1H), 6.19 (d, $J = 7.8$ Hz, 1H), 4.40 (d, $J = 16.7$ Hz, 1H), 4.16 (d, $J = 16.7$ Hz, 1H), 3.94 (s, 1H), 3.74 (s, 3H), 1.21 (s, 3H); ^{13}C NMR (100


MHz, CDCl₃) δ 172.30, 148.84, 138.41, 136.04, 134.61, 129.25, 128.62, 128.37, 128.16, 126.80, 126.77, 126.45, 121.86, 119.49, 109.07, 86.51, 83.29, 52.01, 51.16, 24.65; HRMS (ESI): Exact mass calcd for C₂₄H₂₃NNaO₃ [M+Na]⁺: 396.1570, Found 396.1563.

(2*S,3*R**)-methyl 1-allyl-3-hydroxy-3-methyl-2-phenylindoline-2-carboxylate (8c)**



¹H NMR (400 MHz, CDCl₃) δ 7.37-7.32 (m, 5H), 7.24-7.22 (m, 1H), 7.17-7.13 (m, 1H), 6.84-6.80 (m, 1H), 6.61 (d, *J* = 7.8 Hz, 1H), 6.06-5.97 (m, 1H), 5.36-5.24 (m, 2H), 3.96 (s, 1H), 3.86-3.80 (m, 1H), 3.72 (s, 3H), 3.58-3.52 (m, 1H), 1.07 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.34, 148.74, 136.09, 134.77, 134.61, 129.14, 128.22, 128.09, 127.02, 121.78, 119.27, 116.19, 108.56, 86.30, 83.31, 51.97, 49.86, 25.09; HRMS (ESI): Exact mass calcd for C₂₀H₂₁NNaO₃ [M+Na]⁺: 346.1414, Found 346.1410.

(2*S,3*R**)-methyl 1-benzyl-5-chloro-3-hydroxy-3-methyl-2-phenylindoline-2-carboxylate (8d)**




¹H NMR (400 MHz, CDCl₃) δ 7.40-7.26 (m, 10H), 7.22 (d, *J* = 2.2 Hz, 1H), 6.96 (dd, *J* = 8.3, 2.2 Hz, 1H), 6.08 (d, *J* = 8.4 Hz, 1H), 4.44 (d, *J* = 16.8 Hz, 1H), 4.12 (d, *J* = 16.8 Hz, 1H), 4.12 (s, 1H), 3.74 (s, 3H), 1.16 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.22, 147.19, 137.83, 136.71, 135.44, 128.90, 128.77, 128.49, 128.37, 126.99,

126.71, 126.33, 124.45, 122.35, 110.07, 86.52, 83.03, 52.17, 51.09, 24.90; HRMS (ESI): Exact mass calcd for C₂₄H₂₂ClNNaO₃ [M+Na]⁺: 430.1180, Found 430.1180.

(2*S,3*R**)-methyl**


1-benzyl-5-chloro-3-ethyl-3-hydroxy-2-phenylindoline-2-carboxylate (8e)



¹H NMR (400 MHz, CDCl₃) δ 7.42-7.38 (m, 6H), 7.33-7.29 (m, 4H), 7.22 (d, *J* = 2.2 Hz, 1H), 6.94 (dd, *J* = 8.3, 2.2 Hz, 1H), 6.07 (d, *J* = 8.3 Hz, 1H), 4.68 (d, *J* = 17.0 Hz, 1H), 4.65 (d, *J* = 2.2 Hz, 1H), 3.99 (d, *J* = 17.0 Hz, 1H), 3.71 (s, 3H), 1.53-1.47 (m, 1H), 1.05-0.96 (m, 1H), 0.81 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.05, 146.67, 137.72, 135.82, 134.80, 128.91, 128.39, 128.29, 128.27, 127.04, 126.90, 126.12, 124.58, 123.65, 110.59, 86.95, 85.02, 52.14, 51.07, 29.63, 7.11; HRMS (ESI): Exact mass calcd for C₂₅H₂₄ClNNaO₃ [M+Na]⁺: 444.1337, Found 444.1329.

(2*S,3*R**)-methyl**


1-benzyl-2-(4-bromophenyl)-3-hydroxy-3-methylindoline-2-carboxylate (8f)



¹H NMR (400 MHz, CDCl₃) δ 7.44-7.33 (m, 6H), 7.29-7.23 (m, 4H), 7.06-7.02 (m, 1H), 6.82 (t, *J* = 7.4 Hz, 1H), 6.20 (d, *J* = 7.8 Hz, 1H), 4.35 (d, *J* = 16.7 Hz, 1H), 4.13 (d, *J* = 16.8 Hz, 1H), 3.83 (s, 1H), 3.73 (s, 3H), 1.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.76, 148.68, 138.08, 135.21, 134.38, 131.52, 129.38, 128.70, 128.63, 126.91, 126.38, 122.25, 121.89, 119.75, 109.19, 86.29, 83.29, 52.15, 51.15, 24.86; HRMS (ESI): Exact mass calcd for C₂₄H₂₂BrNNaO₃ [M+Na]⁺: 474.0675, Found 474.0668.


(2*S,3*R**)-methyl**

1-benzyl-2-(3-bromophenyl)-3-hydroxy-3-methylindoline-2-carboxylate (8g)



^1H NMR (400 MHz, CDCl_3) δ 7.55 (d, $J = 1.5$ Hz, 1H), 7.46-7.34 (m, 5H), 7.27-7.24 (m, 3H), 7.16 (t, $J = 7.9$ Hz, 1H), 7.06-7.02 (m, 1H), 6.83 (t, $J = 7.4$ Hz, 1H), 6.21 (d, $J = 7.8$ Hz, 1H), 4.37 (d, $J = 16.7$ Hz, 1H), 4.14 (d, $J = 16.8$ Hz, 1H), 3.82 (s, 1H), 3.74 (s, 3H), 1.21 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.59, 148.67, 138.52, 138.06, 134.29, 131.32, 130.11, 129.89, 129.41, 128.69, 126.93, 126.42, 125.47, 122.48, 121.92, 119.77, 109.18, 86.24, 83.44, 52.21, 51.21, 24.97; HRMS (ESI): Exact mass calcd for $\text{C}_{24}\text{H}_{22}\text{BrNNaO}_3$ $[\text{M}+\text{Na}]^+$: 474.0675, Found 474.0674.


(2*S,3*R**)-methyl 1-benzyl-3-hydroxy-3-methyl-2-(*p*-tolyl)indoline-2-carboxylate (8h)**



^1H NMR (400 MHz, CDCl_3) δ 7.41 (d, $J = 7.2$ Hz, 2H), 7.34 (t, $J = 7.5$ Hz, 2H), 7.26 (d, $J = 7.2$ Hz, 2H), 7.21 (d, $J = 8.3$ Hz, 2H), 7.10 (d, $J = 8.0$ Hz, 2H), 7.05-7.01 (m, 1H), 6.82-6.78 (m, 1H), 6.18 (d, $J = 7.8$ Hz, 1H), 4.36 (d, $J = 16.7$ Hz, 1H), 4.16 (d, $J = 16.7$ Hz, 1H), 3.89 (s, 1H), 3.73 (s, 3H), 2.32 (s, 3H), 1.23 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.41, 149.00, 138.53, 137.95, 134.55, 133.02, 129.26, 129.09, 128.60, 126.73, 126.48, 121.88, 119.37, 108.95, 86.42, 83.23, 51.98, 51.15, 24.51, 21.08; HRMS (ESI): Exact mass calcd for $\text{C}_{25}\text{H}_{25}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$: 410.1727, Found 410.1713.


(2*S,3*R**)-methyl**

1-benzyl-3-hydroxy-2-(3-methoxyphenyl)-3-methylindoline-2-carboxylate (8i)



^1H NMR (400 MHz, CDCl_3) δ 7.42 (d, $J = 7.6$ Hz, 2H), 7.34 (t, $J = 7.5$ Hz, 2H), 7.28-7.20 (m, 3H), 7.04-7.02 (m, 1H), 6.93-6.91 (m, 2H), 6.86-6.80 (m, 2H), 6.22 (d, $J = 7.8$ Hz, 1H), 4.45 (d, $J = 16.8$ Hz, 1H), 4.18 (d, $J = 16.9$ Hz, 1H), 4.03 (s, 1H), 3.74 (s, 3H), 3.54 (s, 3H), 1.22 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.30, 159.46, 148.71, 138.49, 137.51, 134.71, 129.39, 129.21, 128.63, 126.77, 126.41, 121.82, 119.57, 119.30, 113.90, 112.31, 108.92, 86.46, 83.33, 54.97, 52.05, 51.09, 24.80; HRMS (ESI): Exact mass calcd for $\text{C}_{25}\text{H}_{25}\text{NNaO}_4$ $[\text{M}+\text{Na}]^+$: 426.1676, Found 426.1670.

Methyl 1-methyl-3-methylene-2-phenylindoline-2-carboxylate (**9**)






^1H NMR (400 MHz, CDCl_3) δ 7.29-7.21 (m, 6H), 7.14-7.10 (m, 1H), 6.62-6.58 (m, 1H), 6.39 (d, $J = 8.0$ Hz, 1H), 5.56 (s, 1H), 5.03 (s, 1H), 3.72 (s, 3H), 2.67 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.87, 150.85, 147.74, 139.03, 129.72, 127.28, 126.88, 126.81, 123.23, 119.43, 116.00, 104.79, 104.67, 78.99, 51.65, 28.60; HRMS (ESI): Exact mass calcd for $\text{C}_{18}\text{H}_{17}\text{NNaO}_2$ $[\text{M}+\text{Na}]^+$: 302.1151, Found 302.1189.

7. NMR spectra for the Products

7.1 NMR spectra for 3


(2*S**,3*R**)-methyl 3-hydroxy-2-phenyl-3-((*E*-styryl)indoline-2-carboxylate (**3a**)









(2*S**,3*R**)-methyl


2-(4-bromophenyl)-3-hydroxy-3-((*E*)-styryl)indoline-2-carboxylate (**3b**)






(2*S**,3*R**)-methyl 3-hydroxy-3-((*E*)-styryl)-2-(*p*-tolyl)indoline-2-carboxylate (**3c**)






(2*S**,3*R**)-methyl


3-hydroxy-2-(3-methoxyphenyl)-3-((*E*)-styryl)indoline-2-carboxylate (**3d**)







(2*S**,3*R**)-methyl



3-hydroxy-2-(2-methoxyphenyl)-3-((*E*)-styryl)indoline-2-carboxylate (3e)






(2*S**,3*R**)-methyl


3-((*E*)-4-chlorostyryl)-3-hydroxy-2-phenylindoline-2-carboxylate (**3f**)






(2*S**,3*R**)-methyl



3-hydroxy-2-phenyl-3-((*E*)-4-(trifluoromethyl)styryl)indoline-2-carboxylate (**3g**)






(2*S**,3*R**)-methyl


3-hydroxy-3-((*E*)-4-methylstyryl)-2-phenylindoline-2-carboxylate (**3h**)






(2*S**,3*R**)-methyl


3-hydroxy-3-((*E*)-4-methoxystyryl)-2-phenylindoline-2-carboxylate (**3i**)









(2*S**,3*R**)-methyl

3-((*E*)-3-chlorostyryl)-3-hydroxy-2-phenylindoline-2-carboxylate (**3j**)







(2*S**,3*R**)-ethyl 3-hydroxy-2-methyl-3-((*E*)-styryl)indoline-2-carboxylate (**3k**)





(2*S**,3*R**)-methyl 3-hydroxy-2,3-diphenylindoline-2-carboxylate (**3I**)





7.2 Analytical Data for 8 and 9

(2*S**,3*R**)-methyl 3-hydroxy-1,3-dimethyl-2-phenylindoline-2-carboxylate (8a)





(2*S**,3*R**)-methyl 1-benzyl-3-hydroxy-3-methyl-2-phenylindoline-2-carboxylate

(8b)






(2*S**,3*R**)-methyl 1-allyl-3-hydroxy-3-methyl-2-phenylindoline-2-carboxylate
(8c)



(2*S,3*R**)-methyl**


1-benzyl-5-chloro-3-hydroxy-3-methyl-2-phenylindoline-2-carboxylate (8d)







(2*S**,3*R**)-methyl



1-benzyl-5-chloro-3-ethyl-3-hydroxy-2-phenylindoline-2-carboxylate (8e)






(2*S**,3*R**)-methyl


1-benzyl-2-(4-bromophenyl)-3-hydroxy-3-methylindoline-2-carboxylate (**8f**)






(2*S**,3*R**)-methyl


1-benzyl-2-(3-bromophenyl)-3-hydroxy-3-methylindoline-2-carboxylate (**8g**)





JCC20034-13C(CDCI3)




JCC20034-13C(CDCI3)




(2*S**,3*R**)-methyl 1-benzyl-3-hydroxy-3-methyl-2-(*p*-tolyl)indoline-2-carboxylate
(8h)







(2*S**,3*R**)-methyl

1-benzyl-3-hydroxy-2-(3-methoxyphenyl)-3-methylindoline-2-carboxylate (**8i**)





Methyl 1-methyl-3-methylene-2-phenylindoline-2-carboxylate (9)



JCC17864-13C(CDCI3)

